ART signs GE

For patients with residual or recurrent grade 2 isocitrate dehydrogenase (IDH)-mutant gliomas, magnetic resonance imaging (MRI) revealed that daily dosing of vorasidenib, an inhibitor of mutant IDH1 and IDH2 enzymes, led to a median progression-free survival of 27.7 months in comparison to 11.1 months in a placebo group, according to new research presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Richard Duszak, MD, and Mina Makary, MD, discuss a number of issues, ranging from demographic trends and NPRPs to physician burnout and medical student recruitment, that figure to impact the radiology workforce now and in the near future.

In a review of patient data from 42 countries, researchers found that standardized typical findings on computed tomography (CT) for COVID-19 had a pooled sensitivity rate of 70 percent and a pooled specificity rate of 90 percent.

An interview with two experts to discuss newly released guidance for using standardized MRI protocols for patients with this condition.

In a large retrospective study involving over 523,000 digital breast tomosynthesis (DBT) exams and over one million digital mammography (DM) exams, researchers found that DBT was associated with significantly lower recall rates but showed no advantage over DM in the diagnosis of interval or advanced breast cancer.

Precision DL, a deep learning-based software which will be available on GE HealthCare’s Omni Legend PET/CT device, reportedly increases the detectability of small, low-contrast lesions by 42 percent.